Glycine-proline-glutamate
Alternative Names: Gly-Pro-Glu; Glypromate; GPELatest Information Update: 02 Oct 2021
At a glance
- Originator Neuren Pharmaceuticals
- Class Neuroprotectants; Oligopeptides; Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Mild cognitive impairment
Most Recent Events
- 28 Aug 2006 Clinical data from a media release have been added to the pharmacokinetics section
- 27 Apr 2006 Neuren Pharmaceuticals has completed a phase II trial in mild cognitive impairment in Australia and New Zealand
- 06 Jun 2005 Glycine-proline-glutamate has received fast track status for mild cognitive impairment by the US FDA